Failure of the Ipsogen MutaScreen kit to detect the JAK2 617V>F mutation in samples with additional rare exon 14 mutations: Implications for clinical testing and report of a novel 618C>F mutation in addition to 617V>F

Blood

Volumn 115, Issue 15, 2010, Pages 3175-3176

  Warshawsky, Ilka ^a   Mularo, Frank ^a   Hren, Carol ^a   Jakubowski, Maureen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

AGAR GEL ELECTROPHORESIS; ALLELE; DIAGNOSTIC KIT; EXON; GENE SEQUENCE; HOMOZYGOSITY; LETTER; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

EID: 77951070801     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-12-257501     Document Type: Letter

References (10)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097. (Pubitemid 47281402)
2. IPSOGEN licenses JAK2 mutation test to improve the diagnosis of bloodbased disorders. March 30, 2006; http://www.ipsogen.com/corporate/ cancerprofiler/ipsogen-news/ipsogen-news/browse/4/article/140/ ipsogen-licensesjak2-mutation-test-to-improve-the-diagnosis-of-blood-based- disorders/. Accessed November 20, 2009.
3. Murugesan G, Aboudola S, Szpurka H, et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol. 2006;125(4):625-633.
4. Xie X, Kottke-Marchant K, Lichtin A, et al. Identification of two novel mutations besides JAK2 V617F in a patient with polycythemia vera [abstract]. J Mol Diagn. 2007;9:H37.
5. Grünebach F, Bross-Bach U, Kanz L, Brossart P. Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera. Leukemia. 2006;20(12):2210-2211. (Pubitemid 44782859)
6. Zhang SJ, Li JY, Li WD, et al. The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. Int J Lab Hematol. 2007;29(1):71-72. (Pubitemid 46089292)
7. Yoo JH, Park TS, Maeng HY, et al. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature. Cancer Genet Cytogenet. 2009;189(1):43-47.
8. Ma W, Kantarjian H, Zhang X, et al. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn. 2009;11(1):49-53.
9. American Civil Liberties Union. ACLU Challenges Patents On Breast Cancer Genes: BRCA. February 17, 2010; http://www.aclu.org/free-speech-womensrights/ aclu-challenges-patents-breast-cancer-genes. Accessed March 16, 2010.
10. Walsh T, Casadei S, Hale Coats K, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295(12):1379-1388.